ImmunoGen,Inc. (NASDAQ:IMGN) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 — RESULTS OF OPERATION AND FINANCIAL CONDITION
On February8, 2019,ImmunoGen,Inc. (Nasdaq: IMGN) issued a press release to announce the company’s financial results for the quarter and year ended December31, 2018. The press release announcing financial results for the quarter and year ended December31, 2018 is included as Exhibit99.1 and incorporated herein by reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d): The following exhibit is being furnished herewith:
IMMUNOGEN INC Exhibit
EX-99.1 2 a19-4244_1ex99d1.htm EX-99.1 Exhibit 99.1 ImmunoGen Reports Recent Progress and 2018 Operating Results Top-Line Data from Phase 3 FORWARD I Mirvetuximab Soravtansine Study on Track for First Half of 2019 Encouraging Clinical Data from Novel IGN Pipeline Highlighted in Two Oral Presentations at ASH 2018 Sale of Kadcyla® Royalty Tail for $65 Million Further Strengthens Financial Position Conference Call to be Held at 8:00 a.m. ET Today Waltham,…
To view the full exhibit click here
About ImmunoGen,Inc. (NASDAQ:IMGN)
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.
